(GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver ...

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Home > Pressemitteilung: Two million euros for better therapy ... MHH molecular biologist investigates the body's own repair programme in the heart muscle and receives the renowned ERC Advanced Grant ...

SAN FRANCISCO - 89bio, Inc. (NASDAQ:ETNB), a biopharmaceutical company specializing in liver and cardiometabolic diseases with a current market capitalization of $1.05 billion, has initiated a public ...

Goldman Sachs & Co. LLC, Leerink Partners and BofA Securities are acting as lead book-running managers and Cantor is acting ...

After missing the primary endpoint in the Phase IIb SYMMETRY trial, Akero Therapeutics’ lead molecule, efruxifermin, showed ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

An approach using engineered small extracellular vesicles from NK cells to DR5 could be a promising strategy for solid tumors ...

The American Cancer Society’s estimates for primary liver cancer and intrahepatic bile duct cancer in the United States for 2025 are: About 42,240 new cases (28,220 in men and 14,020 in women) will be ...

1Division of Digestive and Liver Diseases, Department of Medicine, Irving Cancer Research Center Columbia University Medical Center, New York, New York. 2Columbia University Digestive and Liver ...

When we hear the word "hepatitis," we tend to associate it with cirrhosis and other disorders affecting the liver. But it's not always the case. As with other persistent, chronic infections, hepatitis ...

Hepatitis and cirrhosis are both diseases that affect the liver. Since hepatitis and cirrhosis are in many ways on a continuum of disease, the symptoms may be very similar. However, there are a ...